11R-VIVIT TFA

Cat. No.: HY-P1430A

Molecular Formula: $C_{147}H_{259}N_{67}O_{36}S$

Molecular Weight: 3573.15

Target: Nuclear Factor of activated T Cells (NFAT)

Pathway: Immunology/Inflammation

Storage: Sealed storage, away from moisture
Powder -80°C 2 years
-20°C 1 year
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

RRRRRRRRRRRGGGMAGPHPVIVITGPHEE (TFA salt)

SOLVENT & SOLUBILITY

In Vitro

H_2O : 100 mg/mL (27.99 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.2799 mL	1.3993 mL	2.7987 mL
	5 mM	0.0560 mL	0.2799 mL	0.5597 mL
	10 mM	0.0280 mL	0.1399 mL	0.2799 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy[1].

IC_{50} & Target

NFAT[1]

In Vitro

11R-VIVIT (100 nM) shows a significant reduction of NFAT2 expression in high glucose treated podocytes compared to podocytes treated with normal glucose. 11R-VIVIT attenuates high glucose induced filtration barrier dysfunction of podocytes[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

11R-VIVIT significantly abrogates the increased urinary albumin excretion rates, attenuates glomerular basement membrane (GBM) thickening and podocyte foot process effacement, partially restores podocyte number, inhibits NFAT2 activation and uPAR expression in glomerular podocytes[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Elife. 2022 Aug 22;11:e79957.
- Am J Respir Cell Mol Biol. 2022 Oct 13.
- Acta Pharmacol Sin. 2021 Dec 22.
- bioRxiv. May 18, 2022.
- Research Square Preprint. 2021 Oct.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Zhang L, et al. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice. Br J Pharmacol. 2013;170(2):426-439.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA